The investigational transfemoral EVOQUE tricuspid valve replacement system (Edwards Lifesciences) significantly reduced severity of tricuspid regurgitation and improved quality of life at 30 days in the TRISCEND single-arm early feasibility study (EFS). The device deployed as intended, with no clinically significant paravalvular leak and good safety outcomes, and patients had significant improvements in 6-minute walk